Dasatinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-DASATINIB |
|---|---|
| Type | Drug |
| Aliases | SprycelДазатиніб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-B-ALL DIS-CML |
| Sources | SRC-ELN-CML-2020 SRC-NCCN-MPN-2025 |
Drug Facts
| Class | BCR-ABL1 / SRC-family TKI (2nd-generation) |
|---|---|
| Mechanism | Multi-target TKI of BCR-ABL1 (~325× more potent than imatinib in vitro), SRC kinases, KIT, PDGFR. Active against most imatinib-resistant mutations except T315I. Pulmonary side-effect profile (effusions, pulmonary HTN) is the dose-limiting concern. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Preferred 2nd-gen TKI for younger CML patients targeting deep molecular response + treatment-free remission, OR for Ph+ ALL. AVOID in pulmonary comorbidity (COPD, prior pleural disease, PAH) due to effusion risk.
Used By
Indications
IND-B-ALL-1L-PH-POS- IND-B-ALL-1L-PH-POS
Regimens
REG-2GEN-TKI-CML- 2nd-generation TKI (dasatinib OR nilotinib OR bosutinib by comorbidity matrix) — CML chro...